Download PDF
Journal of Pediatric Neurology 2024; 22(06): 438-443
DOI: 10.1055/s-0044-1786159
Original Article

Phenotypic Variability Related to Mutations in Riboflavin Transporter in Brazilian Children: Pediatric Case Series

Izabela Cristina Macedo Marques
1   Neurology Department, Hospital Pequeno Príncipe, Curitiba, Brazil
,
Mara Lúcia Schmitz Ferreira Santos
1   Neurology Department, Hospital Pequeno Príncipe, Curitiba, Brazil
,
Solena Ziemer Kusma Fidalski
2   Pediatria Department, Hospital Pequeno Príncipe, Curitiba, Brazil
,
Josiane de Souza
3   Medical Genetic Department, Hospital Pequeno Príncipe, Curitiba, Brazil
,
Daniel Almeida do Valle
1   Neurology Department, Hospital Pequeno Príncipe, Curitiba, Brazil
› Author Affiliations Funding None.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Brown–Vialetto–Van Laere syndrome or riboflavin transporter deficiency is a rare and genetically determined condition that results in a spectrum of neurological signs and symptoms from generalized muscle weakness to cranial nerve involvement with medullary symptoms and respiratory failure. Most patients have SLC52A3 gene biallelic variants, but some of them may have impairment of SLC52A2 gene, both related to the cell transport of riboflavin. We report the case of three unrelated Brazilian patients under 18 years of age with this diagnosis confirmed by molecular genetic sequencing. We observed that the clinical manifestations found were compatible with those already described in the literature by age group. Unusual findings of retinitis pigmentosa and immunodeficiency were identified related to pathogenic variants in the SLC52A2 gene. All patients received riboflavin replacement at a therapeutic dose without gastrointestinal intolerance and with clinical improvement after starting treatment.

Keywords

Brown–Vialetto–Van Laere syndrome - Fazio Londe syndrome - riboflavin transporter - riboflavin supplementation


Publication History

Received: 16 August 2023

Accepted: 26 March 2024

Article published online:
24 April 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Foley AR, Menezes MP, Pandraud A. et al. Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2. Brain 2014; 137 (Pt 1): 44-56
    CrossrefPubMedGoogle Scholar
  • 2 Brown CH. Infantile amyotrophic lateral sclerosis of the family type. J Nerv Ment Dis 1894; 19: 707-716
    CrossrefPubMedGoogle Scholar
  • 3 Vialetto E. Contributo alla forma ereditaria della paralisi bulbare progressive. Riv Sper Fren 1936; 40: 1-24
    PubMedGoogle Scholar
  • 4 Van Laere J. [Familial progressive chronic bulbo-pontine paralysis with deafness. A case of Klippel-Trenaunay syndrome in siblings of the same family. Diagnostic and genetic problems]. Rev Neurol (Paris) 1966; 115 (02) 289-295
    PubMedGoogle Scholar
  • 5 Boudin G, Pépin B, Vernant JC, Gautier B, Gouérou H. [Familial case of chronic progressive bulbo-pontine paralysis with deafness]. Rev Neurol (Paris) 1971; 124 (01) 90-92
    PubMedGoogle Scholar
  • 6 Bosch AM, Stroek K, Abeling NG, Waterham HR, Ijlst L, Wanders RJ. The Brown-Vialetto-Van Laere and Fazio Londe syndrome revisited: natural history, genetics, treatment and future perspectives. Orphanet J Rare Dis 2012; 7: 83
    CrossrefPubMedGoogle Scholar
  • 7 Mosegaard S, Bruun GH, Flyvbjerg KF. et al. An intronic variation in SLC52A1 causes exon skipping and transient riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Mol Genet Metab 2017; 122 (04) 182-188
    CrossrefPubMedGoogle Scholar
  • 8 Fennessy JR, Cornett KMD, Burns J, Menezes MP. Benefit of high-dose oral riboflavin therapy in riboflavin transporter deficiency. J Peripher Nerv Syst 2023; 28 (03) 308-316
    CrossrefPubMedGoogle Scholar
  • 9 Subramanian VS, Sabui S, Teafatiller T, Bohl JA, Said HM. Structure/functional aspects of the human riboflavin transporter-3 (SLC52A3): role of the predicted glycosylation and substrate-interacting sites. Am J Physiol Cell Physiol 2017; 313 (02) C228-C238
    CrossrefPubMedGoogle Scholar
  • 10 Bamaga AK, Maamari RN, Culican SM, Shinawi M, Golumbek PT. Child Neurology: Brown-Vialetto-Van Laere syndrome: dramatic visual recovery after delayed riboflavin therapy. Neurology 2018; 91 (20) 938-941
    CrossrefPubMedGoogle Scholar
  • 11 Manole A, Fratta P, Houlden H. Recent advances in bulbar syndromes: genetic causes and disease mechanisms. Curr Opin Neurol 2014; 27 (05) 506-514
    CrossrefPubMedGoogle Scholar
  • 12 Yao Y, Yonezawa A, Yoshimatsu H, Masuda S, Katsura T, Inui K. Identification and comparative functional characterization of a new human riboflavin transporter hRFT3 expressed in the brain. J Nutr 2010; 140 (07) 1220-1226
    CrossrefPubMedGoogle Scholar
  • 13 Yamamoto S, Inoue K, Ohta KY. et al. Identification and functional characterization of rat riboflavin transporter 2. J Biochem 2009; 145 (04) 437-443
    CrossrefPubMedGoogle Scholar
  • 14 Colasuonno F, Marioli C, Tartaglia M, Bertini E, Compagnucci C, Moreno S. New insights into the neurodegeneration mechanisms underlying riboflavin transporter deficiency (RTD): involvement of energy dysmetabolism and cytoskeletal derangement. Biomedicines 2022; 10 (06) 1329
    CrossrefPubMedGoogle Scholar
  • 15 Bandettini Di Poggio M, Monti Bragadin M, Reni L. et al. Brown-Vialetto-Van Laere syndrome: clinical and neuroradiological findings of a genetically proven patient. Amyotroph Lateral Scler Frontotemporal Degener 2014; 15 (1–2): 141-144
    CrossrefPubMedGoogle Scholar
  • 16 Kendall FP, McCreary EK, Provance PG. Muscles: Testing and Function, with Posture and Pain. 5th ed.. Lippincott Williams & Wilkins; 2005
    Google Scholar
  • 17 O'Callaghan B, Bosch AM, Houlden H. An update on the genetics, clinical presentation, and pathomechanisms of human riboflavin transporter deficiency. J Inherit Metab Dis 2019; 42 (04) 598-607
    CrossrefPubMedGoogle Scholar
  • 18 Kranthi P, Garuda BR, Gopi S, Kumar TS. Brown-Vialetto-Van Laere syndrome: a rare case report of MND mimic. Neurol India 2020; 68 (05) 1217-1219
    CrossrefPubMedGoogle Scholar
  • 19 Amir F, Atzinger C, Massey K. et al. The clinical journey of patients with riboflavin transporter deficiency type 2. J Child Neurol 2020; 35 (04) 283-290
    CrossrefPubMedGoogle Scholar
  • 20 Srour M, Putorti ML, Schwartzentruber J. et al; FORGE Canada Consortium. Mutations in riboflavin transporter present with severe sensory loss and deafness in childhood. Muscle Nerve 2014; 50 (05) 775-779
    CrossrefPubMedGoogle Scholar
  • 21 Cosgrove J, Datta S, Busby M. Adult onset Brown-Vialetto-Van Laere syndrome with opsoclonus and a novel heterozygous mutation: a case report. Clin Neurol Neurosurg 2015; 128: 1-3
    CrossrefPubMedGoogle Scholar
  • 22 Alberca R, Montero C, Ibañez A, Segura DI, Miranda-Nieves G. Progressive bulbar paralysis associated with neural deafness. A nosological entity. Arch Neurol 1980; 37 (04) 214-216
    CrossrefPubMedGoogle Scholar
  • 23 Manole A, Jaunmuktane Z, Hargreaves I. et al. Clinical, pathological and functional characterization of riboflavin-responsive neuropathy. Brain 2017; 140 (11) 2820-2837
    CrossrefPubMedGoogle Scholar
  • 24 Rizzo F, Ramirez A, Compagnucci C. et al. Genome-wide RNA-seq of iPSC-derived motor neurons indicates selective cytoskeletal perturbation in Brown-Vialetto disease that is partially rescued by riboflavin. Sci Rep 2017; 7: 46271
    CrossrefPubMedGoogle Scholar
  • 25 Becherucci V, Bacci GM, Marziali E, Sodi A, Bambi F, Caputo R. The new era of therapeutic strategies for the treatment of retinitis pigmentosa: a narrative review of pathomolecular mechanisms for the development of cell-based therapies. Biomedicines 2023; 11 (10) 2656
    CrossrefPubMedGoogle Scholar
  • 26 Schramm M, Wiegmann K, Schramm S. et al. Riboflavin (vitamin B2 ) deficiency impairs NADPH oxidase 2 (Nox2) priming and defense against Listeria monocytogenes . Eur J Immunol 2014; 44 (03) 728-741
    CrossrefPubMedGoogle Scholar
  • 27 Mazur-Bialy AI, Buchala B, Plytycz B. Riboflavin deprivation inhibits macrophage viability and activity - a study on the RAW 264.7 cell line. Br J Nutr 2013; 110 (03) 509-514
    CrossrefPubMedGoogle Scholar
  • 28 Allison T, Roncero I, Forsyth R, Coffman K, Pichon JL. Brown-Vialetto-Van Laere syndrome as a mimic of neuroimmune disorders: 3 cases from the clinic and review of the literature. J Child Neurol 2017; 32 (06) 528-532
    CrossrefPubMedGoogle Scholar
  • 29 Quaio CRDC, Moreira CM, Novo-Filho GM. et al. Diagnostic power and clinical impact of exome sequencing in a cohort of 500 patients with rare diseases. Am J Med Genet C Semin Med Genet 2020; 184 (04) 955-964
    CrossrefPubMedGoogle Scholar
  • 30 Sardh E, Harper P, Penz C. et al. SSIEM 2016 Annual Symposium - Abstracts. J Inherit Metab Dis 2016; 39: 35-284
    PubMedGoogle Scholar
  • 31 Console L, Tolomeo M, Cosco J, Massey K, Barile M, Indiveri C. Impact of natural mutations on the riboflavin transporter 2 and their relevance to human riboflavin transporter deficiency 2. IUBMB Life 2022; 74 (07) 618-628
    CrossrefPubMedGoogle Scholar
  • 32 Yilmaz O, Gundogdu O, Tunc AA, Cakir M. Audiologic results of child with BVVL syndrome. Ann Med Res 2023; 30 (08) 827-978
    PubMedGoogle Scholar
  • 33 Bosch AM, Abeling NGGM, Ijlst L. et al. Brown-Vialetto-Van Laere and Fazio Londe syndrome is associated with a riboflavin transporter defect mimicking mild MADD: a new inborn error of metabolism with potential treatment. J Inherit Metab Dis 2011; 34 (01) 159-164
    CrossrefPubMedGoogle Scholar
  • 34 Green P, Wiseman M, Crow YJ. et al. Brown-Vialetto-Van Laere syndrome, a ponto-bulbar palsy with deafness, is caused by mutations in c20orf54. Am J Hum Genet 2010; 86 (03) 485-489
    CrossrefPubMedGoogle Scholar
  • 35 Johnson JO, Gibbs JR, Van Maldergem L, Houlden H, Singleton AB. Exome sequencing in Brown-Vialetto-van Laere syndrome. Am J Hum Genet 2010; 87 (04) 567-569 , author reply 569–570
    CrossrefPubMedGoogle Scholar
  • 36 Malafronte P, Clark HB, Castaneda-Sanchez I, Raisanen J, Hatanpaa KJ. Brown-Vialetto-Van Laere syndrome: clinical and neuropathologic findings with immunohistochemistry for C20orf54 in three affected patients. Pediatr Dev Pathol 2013; 16 (05) 364-371
    CrossrefPubMedGoogle Scholar
  • 37 Hossain MA, Obaid A, Rifai M. et al. Early onset of Fazio-Londe syndrome: the first case report from the Arabian Peninsula. Hum Genome Var 2017; 4: 17018
    CrossrefPubMedGoogle Scholar
  • 38 Frederick AL, Yang JH, Schneider S. et al. To be or no B2: a rare cause of stridor and weakness in a toddler. Child Neurol Open 2021; 8: 2329048X2110307
    CrossrefPubMedGoogle Scholar
  • 39 Bashford JA, Chowdhury FA, Shaw CE. Remarkable motor recovery after riboflavin therapy in adult-onset Brown-Vialetto-Van Laere syndrome. Pract Neurol 2017; 17 (01) 53-56
    CrossrefPubMedGoogle Scholar
  • 40 Carey G, Kuchcinski G, Gauvrit F. et al. Three cases of adult-onset Brown-Vialetto-Van Laere syndrome: Novel variants in SLC52A3 gene and MRI abnormalities. Neuromuscul Disord 2021; 31 (08) 752-755
    CrossrefPubMedGoogle Scholar